Effect of the HDAC inhibitor vorinostat on the osteogenic differentiation of mesenchymal stem cells in vitro and bone formation in vivo

Impaired osteogenic differentiation of mesenchymal stem cells derived from multiple myeloma patients is associated with a blockade in the deactivation of the Notch signaling pathway

(2012) S Xu et al.   LEUKEMIA

Suberoylanilide hydroxamic acid (SAHA; vorinostat) causes bone loss by inhibiting immature osteoblasts

(2011) Meghan E. McGee-Lawrence et al.   BONE

A novel role for CCL3 (MIP-1α) in myeloma-induced bone disease via osteocalcin downregulation and inhibition of osteoblast function

(2011) S Vallet et al.   LEUKEMIA

Tumor–host cell interactions in the bone disease of myeloma

(2010) Jessica A. Fowler et al.   BONE

Histone deacetylases in skeletal development and bone mass maintenance

(2010) Meghan E. McGee-Lawrence et al.   GENE

The Histone Deacetylase Inhibitor, Vorinostat, Reduces Tumor Growth at the Metastatic Bone Site and Associated Osteolysis, but Promotes Normal Bone Loss

(2010) J. Pratap et al.   MOLECULAR CANCER THERAPEUTICS

Histone deacetylase inhibitors decrease proliferation potential and multilineage differentiation capability of human mesenchymal stem cells

(2009) S. Lee et al.   CELL PROLIFERATION

Phase I Study of Vorinostat in Combination with Bortezomib for Relapsed and Refractory Multiple Myeloma

(2009) A. Badros et al.   CLINICAL CANCER RESEARCH

Vorinostat enhances the antimyeloma effects of melphalan and bortezomib

(2009) Richard A. Campbell et al.   EUROPEAN JOURNAL OF HAEMATOLOGY

Epigenetic control of skull morphogenesis by histone deacetylase 8

(2009) M. Haberland et al.   GENES & DEVELOPMENT

Phase II Trial of Vorinostat in Recurrent Glioblastoma Multiforme: A North Central Cancer Treatment Group Study

(2009) Evanthia Galanis et al.   JOURNAL OF CLINICAL ONCOLOGY

Mesenchymal stem cells from multiple myeloma patients display distinct genomic profile as compared with those from normal donors

(2009) M Garayoa et al.   LEUKEMIA

The effects of JNJ-26481585, a novel hydroxamate-based histone deacetylase inhibitor, on the development of multiple myeloma in the 5T2MM and 5T33MM murine models

(2009) S Deleu et al.   LEUKEMIA

Gene Therapy Using TRAIL-Secreting Human Umbilical Cord Blood-Derived Mesenchymal Stem Cells against Intracranial Glioma

(2008) S. M. Kim et al.   CANCER RESEARCH

Phase I trial of oral vorinostat (suberoylanilide hydroxamic acid, SAHA) in patients with advanced multiple myeloma

(2008) Paul Richardson et al.   LEUKEMIA & LYMPHOMA

Histone Deacetylase Inhibitors Promote Apoptosis and Senescence in Human Mesenchymal Stem Cells

(2008) Giovanni Di Bernardo et al.   STEM CELLS AND DEVELOPMENT